atovaquone proguanil
Selected indexed studies
- Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. (Cochrane Database Syst Rev, 2021) [PMID:33459345]
- Atovaquone/proguanil-induced autoimmune-like hepatitis. (Hepatol Commun, 2017) [PMID:29404460]
- Atovaquone-proguanil for prophylaxis and treatment of malaria. (Ann Pharmacother, 2003) [PMID:12921511]
_Worker-drafted node — pending editorial review._
Connections
atovaquone proguanil is a side effect of
Sources
- Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria. (2021) pubmed
- Atovaquone/proguanil-induced autoimmune-like hepatitis. (2017) pubmed
- Atovaquone-proguanil for prophylaxis and treatment of malaria. (2003) pubmed
- Atovaquone/proguanil for the prophylaxis and treatment of malaria. (2005) pubmed
- Atovaquone and proguanil hydrochloride for treatment of malaria. (1999) pubmed
- Atovaquone and proguanil hydrochloride: a review of nonclinical studies. (1999) pubmed
- Atovaquone/proguanil for plasmodium falciparum malaria. (2002) pubmed
- Atovaquone and proguanil hydrochloride for prophylaxis of malaria. (1999) pubmed
- The safety of atovaquone-proguanil for the prevention and treatment of malaria in pregnancy: A systematic review. (2019) pubmed
- Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. (2003) pubmed